C3N-01415
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 71.20602327
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.410
- PROTEIN_SECRETION+0.340
- OXIDATIVE_PHOSPHORYLATION+0.290
- INTERFERON_GAMMA_RESPONSE+0.280
- GLYCOLYSIS+0.230
- MTORC1_SIGNALING+0.180
- FATTY_ACID_METABOLISM+0.170
- ADIPOGENESIS+0.140
- COAGULATION+0.140
- SPERMATOGENESIS+0.140
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.360
- TGF_BETA_SIGNALING-0.350
- TNFA_SIGNALING_VIA_NFKB-0.330
- MITOTIC_SPINDLE-0.280
- UV_RESPONSE_DN-0.240
- G2M_CHECKPOINT-0.210
- HYPOXIA-0.210
- HEDGEHOG_SIGNALING-0.200
- P53_PATHWAY-0.180
- IL2_STAT5_SIGNALING-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-75-5147-01A-01R-1628-07 | — | cohortA1 | 0.770 |
| 2 | AUR-AFUK-TTM1-A-1-0-R-A743-41 | — | B | 0.741 |
| 3 | 45a2676b-25ba-41b0-9e55-08c6eb3a8f2f | — | — | 0.727 |
| 4 | X7c156f05.aaca.4c79.bdb2.94044d5422e8 | — | cohortA1 | 0.724 |
| 5 | SRR10899988 | — | — | 0.722 |
| 6 | TCGA-55-1596-01A-01R-0946-07 | — | cohortA4 | 0.696 |
| 7 | TCGA-73-7499-01A-11R-2187-07 | — | cohortA1 | 0.693 |
| 8 | SRR12696790 | — | — | 0.691 |
| 9 | TCGA-50-6594-01A-11R-1755-07 | — | cohortA1 | 0.678 |
| 10 | MNG85 | — | — | 0.673 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.410 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.340 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.290 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.280 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.230 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.180 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.140 | Inavolisib | — uncovered |
| COAGULATION | 0.140 | Binimetinib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.130 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.120 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.120 | Cobimetinib | — uncovered |
| MYC_TARGETS_V1 | 0.100 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.090 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.080 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.070 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.060 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.050 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.050 | Inavolisib | — uncovered |